Xianjun Yu

Dr. Xianjun Yu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2019 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
QZQun Zhao
Qun Zhao
YLYingxiang Liu
Yingxiang Liu
JZJing Zhong
Jing Zhong
YBYun Bi
Yun Bi
YLYongqiang Liu
Yongqiang Liu
XYXianjun Yu
Xianjun Yu
Breast cancer is the most common malignant tumor in women, and progress toward long-term survival has stagnated. Pristimerin, a natural quinonemethide triterpenoid, exhibits potential anti-tumor effects on various cancers. However, the underlying mechanism remains poorly understood. In this study, we found that pristimerin reduced the viability of breast cancer cells in vitro and the growth of xenografts in vivo, and these reductions were accompanied by thioredoxin-1 (Trx-1) inhibition and ASK1 and JNK activation. The results showed that pristimerin inhibited cell cycle progression and triggered cell apoptosis and autophagy. Furthermore, we found that the generation of reactive oxygen species (ROS) was a critical mediator in pristimerin-induced cell death. Enhanced ROS generation by pristimerin activated the ASK1/JNK signaling pathway. Inhibition of ROS with N-acetyl cysteine (NAC) significantly decreased pristimerin-induced cell death by inhibiting the phosphorylation of ASK1 and JNK. Taken together, these results suggest a critical role for the ROS/ASK1/JNK pathway in the anticancer activity of pristimerin.

27 June 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
XYXianjun Yu
Xianjun Yu
QZQun Zhao
Qun Zhao
XZXixi Zhang
Xixi Zhang
HZHaiwei Zhang
Haiwei Zhang
YLYongbo Liu
Yongbo Liu
Hai-Bing ZhangHai-Bing Zhang
Hai-Bing Zhang
Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation

1 January 2021 in Phytomedicine
Verified
Journal Article
Closed access
QZQun Zhao
Qun Zhao
YBYun Bi
Yun Bi
JGJian Guo
Jian Guo
YLYingxiang Liu
Yingxiang Liu
JZJing Zhong
Jing Zhong
XYXianjun Yu
Xianjun Yu

1 November 2020 in Phytomedicine
Verified
Journal Article
Closed access
QZQun Zhao
Qun Zhao
JZJing Zhong
Jing Zhong
YBYun Bi
Yun Bi
YLYongqiang Liu
Yongqiang Liu
YLYingxiang Liu
Yingxiang Liu
XYXianjun Yu
Xianjun Yu

1 January 2020 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
QZQun Zhao
Qun Zhao
YBYun Bi
Yun Bi
JZJing Zhong
Jing Zhong
ZRZiting Ren
Ziting Ren
YLYingxiang Liu
Yingxiang Liu
XYXianjun Yu
Xianjun Yu

Verified
Journal Article
Open access
PDF file
XWXuanbin Wang
Xuanbin Wang
NWNing Wang
Ning Wang
HLHongliang Li
Hongliang Li
MLMing Liu
Ming Liu
FCFengjun Cao
Fengjun Cao
Yibin FengYibin Feng
Yibin Feng
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death and its prognosis remains poor due to the high risk of tumor recurrence and metastasis. Berberine (BBR) is a natural compound derived from some medicinal plants, and accumulating evidence has shown its potent anti-tumor activity with diverse action on tumor cells, including inducing cancer cell death and blocking cell cycle and migration. Molecular targets of berberine involved in its inhibitory effect on the invasiveness remains not yet clear. In this study, we identified that berberine exhibits a potent inhibition on the invasion and migration of HCC cells. This was accompanied by a dose-dependent down-regulation of expression of Cyclooxygenase-2 (COX-2), nuclear factor kappa B (NF-κB), urokinase-type plasminogen activator (uPA) and matrix metalloproteinase (MMP)-9 in berberine-treated HCC cells. Furthermore, berberine inactivated p38 and Erk1/2 signaling pathway in HCC cells. Primarily, this may be attributed to the up-regulation of plasminogen activator inhibitor-1 (PAI-1), a tumor suppressor that can antagonize uPA receptor and down-regulation of uPA. Blockade of uPA receptor-associated pathways leads to reduced invasiveness and motility of berberine-treated HCC cells. In conclusion, our findings identified for the first time that inactivation of uPA receptor by up-regulation of PAI-1 and down-regulation of uPA is involved in the inhibitory effect of berberine on HCC cell invasion and migration.